BCL2 and breast carcinoma: For example, thymic stromal lymphopoietin (TSLP), known for fostering an inflammatory Th2 microenvironment, has been documented to inhibit the progression of breast cancer tumors.[20] Indeed, TSLP has the potential to suppress inflammation in para-tumor tissue in early-stage breast cancer.[21] However, in metastatic disease, TSLP is essential for breast cancer progression through the induction of the anti-apoptosis molecule Bcl-2 in vitro.[22] In our 10-gene signature, TSLP had the most protective effect on OS.